share_log

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

6-K:托勒布替尼在HERCULES 3期研究中达到主要终点,这是第一个也是唯一一个显示非复发继发性进行性多发性硬化症残疾积累减少的研究
美股SEC公告 ·  09/03 10:51
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息